Press Releases

Samsung BIO Insight

Samsung Biologics at BIO Digital 2021

Samsung%20Biologics%20at%20BIO%20Digital%202021_Thumbnail%20(2).png
 

BIO International, the largest biotech event of the year, was held virtually from June 10th to 18th, bringing together more than 6,000 participants from 55 countries as “BIO Digital 2021.” This year’s main agenda was the impact of COVID-19 on the biopharmaceutical industry and the future bioeconomy.

 

Samsung Biologics CEO John Rim delivered the opening remarks sharing the company’s future plans at an exclusive keynote session with Richard N. Haass, President of the Council on Foreign Relations. Samsung Biologics was also involved in various conference events including a Fireside Chat, BioProcess International Theater, and one-on-one partnering sessions. Additionally, Samsung Biologics’ upcoming film, ‘The Role of CDMO: Reimagining Biopharma Ecosystem,’ produced by BBC StoryWorks, a commercial content division of BBC Global News, and presented by ICBA (International Council of Biotechnology Associations), was introduced during a panel discussion at the event.

 

In this article, we will highlight some of the key moments at BIO Digital 2021 and showcase Samsung Biologics’ latest expert insights. 

 

The Future of Samsung Biologics amid the Global Pandemic

 

Since the emergence of the COVID-19 virus and other new life-threatening diseases, it has become clearer that cross-border solidarity and cooperation are crucial in overcoming the pandemic together. Expectations for the biopharmaceutical industry are high as the world awaits a turning point enabled by scientific breakthroughs. Amid such growing attention, John Rim, CEO of Samsung Biologics, gave the opening remarks during a keynote speech on the topic of ‘Breaking Barriers in Foreign Policy,’ hosted by President Richard N. Haass of the Council on Foreign Relations and CEO Jeremy Levin of Ovid Therapeutics. In his speech, Rim highlighted the industry’s continuing efforts and contributions in the battle against COVID-19, including the manufacturing of mRNA vaccines, and also shared the company’s vision and long-term plans to better serve existing and potential clients. 

 

EXCERPTS FROM CEO JOHN RIM’S KEYNOTE SPEECH 

   

EXCERPTS FROM CEO JOHN RIM’S KEYNOTE SPEECH

 

> “Standing alongside our partners, Samsung Biologics is extremely honored and proud to be able to contribute in this battle against COVID-19. As most recently announced, we are fully committed to leveraging our experience in manufacturing technologies to support the aseptic fill and finish of Moderna’s mRNA-1273 vaccine with quality, speed, and efficiency to aid in the fight against this global crisis.”

> “With our leadership in contract manufacturing, Samsung Biologics has set out to become a true end-to-end biologic solution provider with seamless integration with contract development and drug product aseptic fill/finish services including biosafety testing. We are now providing a full array of biologic solutions from cell line & process development to both GMP and non-GMP clinical batch production.”

> “With the sustainability and growth of the biotech industry in mind, our business planning includes 3 areas of expansion:

1) Capacity Expansion: Adding additional capacities and capabilities in Bio Campus II

2) Geographical Expansion: To improve client reach on a global scale as demonstrated by the opening of our US CDO R&D center last year

3) Modality Expansion: To provide more diversified, multimodal state-of-the-art infrastructure. As recently announced, we will be also adding a dedicated production suite for mRNA bulk drug substance to the existing facility by the first half of 2022, which will enable us to rapidly manufacture and supply future vaccines and treatments against multiple targets.”

 

Wrapping up the speech on a forward-looking note, Rim said, “The ongoing global crisis brought us clarity about what is truly important and reminded us of the awesome potential of our industry in altering the course of devastation and bringing hope to the world. Our vision has been, and always will be, to achieve better life through biomedicines. And with the mission to enrich human life with technology and innovation, Samsung Biologics will bring you greater success faster.”

 

What’s Coming Next? - A Conversation with Samsung Biologics from a CDMO Point of View

 

On June 16th, Joon Young Chang, Senior Director of Global Sales and Operations Center, participated in an expert interview session to discuss the emerging trends of the CDMO industry and its partnerships highlighting the unique values that Samsung Biologics delivers to clients. 

 

EXCERPTS FROM SENIOR DIRECTOR JOON Y. CHANG’S SESSION 

 

EXCERPTS FROM SENIOR DIRECTOR JOON Y. CHANG’S SESSION

 

> “The biopharmaceutical market has greatly expanded due to COVID-19, and the need to secure manufacturing facilities to stably supply biopharmaceuticals is increasing rapidly. As the demand for strategic partnerships with contract manufacturing organizations increases, it is becoming more important than ever to offer customized strategies and tailored services to meet the diverse needs of clients.”

> “Upon the COVID-19 pandemic, 'distribution supply chain strategy' has emerged as an important discussion topic in the biopharmaceutical industry. Samsung Biologics has strengthened its supply chain network to enable stable manufacturing and supply of biomedicines even during a time of crisis, and has actively supported multi-sourcing for risk dispersion as well as localization.”

> “Flexibility has also become a keyword in the way we work. Virtual meetings have become essential in our daily lives, and communicating with clients without time and space restrictions have become very important. This trend is expected to continue even in the post pandemic era. As transparent communication and collaboration are becoming more important, 'Digital Transformation' will be a major discussion topic in the future biopharmaceutical industry. Samsung Biologics has been proactively introducing digital technologies in response to the pandemic…Through virtual due diligence, we were able to conduct regulatory inspections and ultimately gain successful approvals for COVID-19 treatments, and we were able to deliver medicines to patients more quickly.”

 

Samsung Biologics and BBC StoryWorks on The Role of CDMO

 

How is biotechnology being used today to tackle tomorrow’s challenges? To answer that question, Samsung Biologics participated in a film “The Role of CDMO: Reimagining the Biopharma Eco-System,” which highlights not only our work and capabilities as a CDMO but also the impact the high-quality biomedicines we manufacture and develop with our clients have on patients globally. The video was introduced at a panel discussion during the event, and it will be released on June 23rd on the Samsung Biologics website and social media. 

 

The vision of Samsung Biologics has been, and always will be, to achieve better life through biomedicines. 

The vision of Samsung Biologics has been, and always will be,

to achieve better life through biomedicines.  

 

As reinforced at BIO Digital 2021, Samsung Biologics is committed to becoming globally leading CDMO and contributing to better life for humanity throughout the pandemic and beyond. 

Samsung%20Biologics%20at%20BIO%20Digital%202021_Thumbnail%20(2).png
 

 

BIO International, the largest biotech event of the year, was held virtually from June 10th to 18th, bringing together more than 6,000 participants from 55 countries as “BIO Digital 2021.” This year’s main agenda was the impact of COVID-19 on the biopharmaceutical industry and the future bioeconomy.

 

Samsung Biologics CEO John Rim delivered the opening remarks sharing the company’s future plans at an exclusive keynote session with Richard N. Haass, President of the Council on Foreign Relations. Samsung Biologics was also involved in various conference events including a Fireside Chat, BioProcess International Theater, and one-on-one partnering sessions. Additionally, Samsung Biologics’ upcoming film, ‘The Role of CDMO: Reimagining Biopharma Ecosystem,’ produced by BBC StoryWorks, a commercial content division of BBC Global News, and presented by ICBA (International Council of Biotechnology Associations), was introduced during a panel discussion at the event.

 

In this article, we will highlight some of the key moments at BIO Digital 2021 and showcase Samsung Biologics’ latest expert insights. 

 

The Future of Samsung Biologics amid the Global Pandemic

 

Since the emergence of the COVID-19 virus and other new life-threatening diseases, it has become clearer that cross-border solidarity and cooperation are crucial in overcoming the pandemic together. Expectations for the biopharmaceutical industry are high as the world awaits a turning point enabled by scientific breakthroughs. Amid such growing attention, John Rim, CEO of Samsung Biologics, gave the opening remarks during a keynote speech on the topic of ‘Breaking Barriers in Foreign Policy,’ hosted by President Richard N. Haass of the Council on Foreign Relations and CEO Jeremy Levin of Ovid Therapeutics. In his speech, Rim highlighted the industry’s continuing efforts and contributions in the battle against COVID-19, including the manufacturing of mRNA vaccines, and also shared the company’s vision and long-term plans to better serve existing and potential clients. 

 

EXCERPTS FROM CEO JOHN RIM’S KEYNOTE SPEECH 

   

EXCERPTS FROM CEO JOHN RIM’S KEYNOTE SPEECH

 

> “Standing alongside our partners, Samsung Biologics is extremely honored and proud to be able to contribute in this battle against COVID-19. As most recently announced, we are fully committed to leveraging our experience in manufacturing technologies to support the aseptic fill and finish of Moderna’s mRNA-1273 vaccine with quality, speed, and efficiency to aid in the fight against this global crisis.”

> “With our leadership in contract manufacturing, Samsung Biologics has set out to become a true end-to-end biologic solution provider with seamless integration with contract development and drug product aseptic fill/finish services including biosafety testing. We are now providing a full array of biologic solutions from cell line & process development to both GMP and non-GMP clinical batch production.”

> “With the sustainability and growth of the biotech industry in mind, our business planning includes 3 areas of expansion:

1) Capacity Expansion: Adding additional capacities and capabilities in Bio Campus II

2) Geographical Expansion: To improve client reach on a global scale as demonstrated by the opening of our US CDO R&D center last year

3) Modality Expansion: To provide more diversified, multimodal state-of-the-art infrastructure. As recently announced, we will be also adding a dedicated production suite for mRNA bulk drug substance to the existing facility by the first half of 2022, which will enable us to rapidly manufacture and supply future vaccines and treatments against multiple targets.”

 

Wrapping up the speech on a forward-looking note, Rim said, “The ongoing global crisis brought us clarity about what is truly important and reminded us of the awesome potential of our industry in altering the course of devastation and bringing hope to the world. Our vision has been, and always will be, to achieve better life through biomedicines. And with the mission to enrich human life with technology and innovation, Samsung Biologics will bring you greater success faster.”

 

What’s Coming Next? - A Conversation with Samsung Biologics from a CDMO Point of View

 

On June 16th, Joon Young Chang, Senior Director of Global Sales and Operations Center, participated in an expert interview session to discuss the emerging trends of the CDMO industry and its partnerships highlighting the unique values that Samsung Biologics delivers to clients. 

 

EXCERPTS FROM SENIOR DIRECTOR JOON Y. CHANG’S SESSION 

 

EXCERPTS FROM SENIOR DIRECTOR JOON Y. CHANG’S SESSION

 

> “The biopharmaceutical market has greatly expanded due to COVID-19, and the need to secure manufacturing facilities to stably supply biopharmaceuticals is increasing rapidly. As the demand for strategic partnerships with contract manufacturing organizations increases, it is becoming more important than ever to offer customized strategies and tailored services to meet the diverse needs of clients.”

> “Upon the COVID-19 pandemic, 'distribution supply chain strategy' has emerged as an important discussion topic in the biopharmaceutical industry. Samsung Biologics has strengthened its supply chain network to enable stable manufacturing and supply of biomedicines even during a time of crisis, and has actively supported multi-sourcing for risk dispersion as well as localization.”

> “Flexibility has also become a keyword in the way we work. Virtual meetings have become essential in our daily lives, and communicating with clients without time and space restrictions have become very important. This trend is expected to continue even in the post pandemic era. As transparent communication and collaboration are becoming more important, 'Digital Transformation' will be a major discussion topic in the future biopharmaceutical industry. Samsung Biologics has been proactively introducing digital technologies in response to the pandemic…Through virtual due diligence, we were able to conduct regulatory inspections and ultimately gain successful approvals for COVID-19 treatments, and we were able to deliver medicines to patients more quickly.”

 

 

Samsung Biologics and BBC StoryWorks on The Role of CDMO

 

How is biotechnology being used today to tackle tomorrow’s challenges? To answer that question, Samsung Biologics participated in a film “The Role of CDMO: Reimagining the Biopharma Eco-System,” which highlights not only our work and capabilities as a CDMO but also the impact the high-quality biomedicines we manufacture and develop with our clients have on patients globally. The video was introduced at a panel discussion during the event, and it will be released on June 23rd on the Samsung Biologics website and social media. 

 

The vision of Samsung Biologics has been, and always will be, to achieve better life through biomedicines. 

The vision of Samsung Biologics has been, and always will be,

to achieve better life through biomedicines.  

 

As reinforced at BIO Digital 2021, Samsung Biologics is committed to becoming globally leading CDMO and contributing to better life for humanity throughout the pandemic and beyond. 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION